Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt

Research output: Contribution to journalArticle

25 Citations (Scopus)
564 Downloads (Pure)


Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
Original languageEnglish
Pages (from-to)1-386
Number of pages386
JournalHealth Technology Assessment
Issue number29
Publication statusPublished - Jul 2013


Cite this